# Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-safety-assessment-of-oligonucleotide-based-therapeutics/98302410-dce1-4d17-92eb-6b05f834b01c

> FDA guidance document: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics. Issue date: November 15, 2024. Get complete insights and analysis.

---

## Details

- Title: Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-11-15
- Comment Close Date: 2025-01-14
- Last Changed: 2024-11-15
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-4624">FDA-2024-D-4624</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Monoclonal Antibodies: Streamlined Nonclinical Safety Studies: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/monoclonal-antibodies-streamlined-nonclinical-safety-studies-draft-guidance-for-industry/439cec36-0e7d-4c02-88e4-7a0af7b47fa4)
- [Data Integrity for In Vivo Bioavailability and Bioequivalence Studies](https://www.globalkeysolutions.net/guidances/guidance-document/data-integrity-for-in-vivo-bioavailability-and-bioequivalence-studies/04d979b3-3f1d-4515-b9c1-f1a8fb7fb19b)